From today's announcement: "A key question that was not answered...

From today's announcement:

"A key question that was not answered by VitroCARD was how much of the healing was due to VF001 and how much to “usual care” –this is the question that the Phase 2 trial (VF00102) was designed to answer, in order to meet the requirements of both EU and US regulatory authorities"


So now they tell us that this question was not answered. This is so different to what we have been told before imho.

Without doing much digging, and I sure somebody will, these are just a few quotes from just ONE presentation:

"Proven potency and safety."


"Effective corporate turnaround, de-risked lead program"



"Probability of healing in Mild and moderate patients is 93% and 65% respectively."



"12 week data showed statistically significant wound area reduction from baseline (p=0.003)"



"VF-001 shows Improved and efficient healing"


"Poised for Clinical and Commercial Success"



"De-risked product with prior clinical experience demonstrated safety and efficacy"



https://www.asx.com.au/asxpdf/20161122/pdf/43d2my8lrfwt6t.pdf